Research Article | Open Access
Juan Castro, Luis Sanchez, María Teresa Nuñez, Ming Lu, Tomas Castro, Hamid R. Sharifi, Christer Ericsson, "Screening Circulating Tumor Cells as a Noninvasive Cancer Test in 3388 Individuals from High-Risk Groups (ICELLATE2)", Disease Markers, vol. 2018, Article ID 4653109, 5 pages, 2018. https://doi.org/10.1155/2018/4653109
Screening Circulating Tumor Cells as a Noninvasive Cancer Test in 3388 Individuals from High-Risk Groups (ICELLATE2)
Cancer is known to spread up to 12 years before clinical symptoms occur, but few screening tests exist. Early detection would give the opportunity for early treatment, potentially improving prognosis. To this end, 3388 subjectively healthy individuals of age 45 to 80 who had been exposed to cancer risk factors were screened for the occurrence of circulating tumor cells in their blood. Presence of circulating tumor cells is a suspicious finding indicative of spreading cancer, since cancer metastasizes by way of the blood and offers the opportunities to (a) follow up the individual clinically based on established guidelines for early detection of cancer and (b) evaluate the cells further analytically. 107 individuals showed one or more circulating tumor cells in a 7.5 ml blood sample, which constitutes a positive circulating tumor cell test, based on the iCellate IsoPic™ laboratory test. That number compares favorably with the cancer incidence per 100,000 people/year that is 157.1 in Peru, given that a high-risk group of individuals was screened and that the screening results would be expected to correspond to an accumulated incidence of up to 12 years. The present findings therefore identify screening for circulating tumor cells as a promising new test.
Epithelial cancers spread by inappropriately invading the basement membrane of extracellular matrix fibers, a key microscopic observation by clinical pathologists that forms part of the diagnosis of cancer. The invading cells may invade locally or may enter the lymph or blood vessels. The result is local or systemic spread of the cancer cells that may result in metastases. Clinical observation  and experimental testing  demonstrate that the spread can occur early in the disease progression, well before the primary tumor would give symptoms, be visible by medical imaging , or be detectable by serum tumor markers [3–5]. Screening for CTCs in the blood is therefore an inherently promising approach to early detection of cancer.
The first generation of CTC isolation instrumentation, which used the EpCAM cell surface biomarker as an immunoaffinity tag for cancer cell detection, followed up by verifying the epithelial nature of the detected cells by being DAPI-positive (i.e., having a cell nucleus), cytokeratin-positive (i.e., being epithelial), and CD45-negative (i.e., not a leucocyte), established the prognostic relevance of quantifying CTCs in 3 major late-stage cancers [6–8]. It was discovered that CTCs are extremely rare in healthy subjects and patients with nonmalignant diseases but present in various metastatic carcinomas with a wide range of frequencies . Attempts to follow up on that initial promise for early detection of cancer were however disappointing [10, 11]. This may be related to the limitation of the cell surface marker used, EpCAM, since it may be lost during disease progression or depending on the state of the cells. In addition, genomic analyses of single CTCs remain a challenge to this day, although recent progress in sequencing technology offers new promise. The understanding now is that a more universal, marker-independent 2nd-generation approach to CTC isolation is required . One such 2nd-generation CTC isolation instrument is the iCellate’s IsoPic. In addition, it has previously been demonstrated that an IsoPic prototype could isolate CTCs from a patient with peritoneal carcinomatosis [12, 13]. The isolated cells could also be demonstrated to be genetically abnormal, consistent with being cancerous (Castro and Ericsson, unpublished data). The iCellate IsoPic would therefore seem to be a promising test to screen asymptomatic individuals for suspicious cells that can then be tested further, with the hope of the screening leading to the early detection of cancer.
In the present paper, we report the results of screening 3388 subjectively healthy individuals, with no cancer diagnosis, but with an increased risk of developing cancer based on age and having been exposed to other risk factors. We find 107 individuals carrying cells in their blood that satisfy the established criteria for CTCs. The iCellate IsoPic therefore seems to provide a promising cell sample for the early detection of cancer.
3388 subjectively healthy people, with no previous history of cancer, were screened for the presence of any cells in a 7.5 ml blood sample that comply with the established definition of a CTC, such as the cells shown in Figure 1. Those cells were counted. 3281 subjects were negative for any such cells. 107 samples were positive for CTCs (see Table 1). The numbers of CTCs varied from 1 to 10. The positive patient samples were divided over the risk groups as follows: (1) heavy cigarette smoker (≥2 packets per day) more than 10 years: 12%; (2) family history of cancer: 82%; (3) chronic infection of hepatitis B virus (HBV) or hepatitis C virus (HCV): 1.5%; and (4) elevated prostate-specific antigen (PSA) level (≥4 ng/ml): 4.5%. The samples were enriched about 7500-fold for CTCs, with about 10,000 DAPI and CD45-positive leucocytes left in the sample after enrichment. The attending physician decoded any positive results, and a systematic recall program was initiated. This program is ongoing. The results suggest that screening for CTCs is already a valuable screening tool, whose merits will be further enhanced by further clinical follow-up and by molecular analyses of the isolated cells.
The present study found that cells meeting the established criteria for CTCs can indeed be detected among subjectively healthy individuals with increased risk of cancer, suggesting those cells may be a promising new sample type for cancer health screening and early detection. These findings are in line with the clinical information that primary tumors spread metastases by way of the blood years before they give symptoms and can be diagnosed by medical imaging , but was by no means self-evident. The CellSearch technique, FDA-approved since 2004 for late-stage breast, prostate, or colorectal cancer, has not been able to meet expectations of establishing a screening test for spreading cancer. The discrepancy may be due to that the CellSearch method relies on a cell surface marker that may not be present on all cancer cells, making the IsoPic both more sensitive and more representative of the entire panorama of cancer cells .
The age-standardized cancer rate, incidence per 100,000 people/year is 157.1 in Peru, or about one-twentieth of the CTC incidence found in the present study. We think there are two reasonable explanations for the discrepancy between the clinical incidence of cancer and the incidence of CTCs: (1) this is a high-risk group in terms of age and four other risk factors, (2) since the spread of a tumor may occur up to 12 years  before it gives clinical symptoms, and given that the tumor spreads by means of CTCs, we think that up to 12 multiples of the yearly clinical incidence may be reasonable for the CTCs, based on the assumption that any cancer developing clinically one year later, two years later, and so on up to 12 years later would be discovered at any one given time by the CTC screen, but before symptom debut. A parallel study, with 1585 asymptomatic average-risk age-matched individuals, showed 27 samples positive for CTC, or 1.7% (manuscript submitted for publication). Thus, we think that the CTC findings entirely align with reasonable assumptions of the disease mechanism. Future clinical follow-ups, using established criteria for early cancer detection , and more detailed analyses of the CTCs will serve to further clarify the relationship between CTC incidence and clinical incidence.
The established criteria for identification of CTCs such as DAPI positivity, cytokeratin positivity, and CD45 negativity  demonstrate only that the isolated cells show traces of being epithelial and not of being an immune cell, but do not in and of themselves demonstrate that the cell is a cancer cell. Epithelial cells should however not be present in the circulation. Their very existence is therefore a warning sign and a suspicious finding that should trigger a clinical follow-up, since no CTCs should be present in circulation. Future clinical trials will establish the opportunities and limitations of this new CTC detection and quantification. In the meantime, since a screening test is not intended to be diagnostic on its own, individuals with suspicious findings must be referred to a physician for diagnosis and any consequent treatment . Established criteria for the early detection of a variety of cancers exist . Following up on a positive CTC test with established cancer early detection may be medically and health economically advantageous.
Previous experimental studies of cancer  have shown that only genetically abnormal cells can seed metastases, not similar cells with functionally normal genomes. To bring cell-based diagnosis of cancer to its logical conclusion therefore requires that the isolated cells are also subjected to either functional tests for the hallmarks of cancer [18, 19] or are genetically sequenced, followed by the relevant bioinformatics analysis, to establish their cancerous nature. Such tests, in conjunction with the isolation of the inappropriate cells, would be expected to enhance the clinical relevance of the CTC detection and quantification. It should therefore be clear that to go beyond a suspicious finding and towards establishing that the cells are actually cancerous, even if at a very early stage, will require genetic analyses of the cells. For those cases, the present sample type would provide an ideal sample.
It will also be of interest to compare the genetic analyses of isolated CTCs to those of free circulating tumor DNA, ctDNA, to establish the merits of each sample type. The ctDNA sample is easily available, but is degraded, diluted, and admixed with normal DNA and has lost its cellular context, but may still provide a useful alternative when those negative factors are of lesser importance. Since the CTCs are the actual vehicles of metastatic spread and provide a highly concentrated and pure sample in its cellular context, it would be expected that CTCs would remain the “gold standard” of blood-based cancer testing.
Summary: CTCs can be detected in asymptomatic individuals. A positive CTC-screening test is a suspicious finding that should be followed up clinically. The value of the test will be further enhanced following clinical trials and by adding new molecular tests of the isolated circulating tumor cells.
ICELLATE2 is an all-comer, single-center trial including individuals in the age of 45–80 years and belonging to any of the 4 risk groups: (1) heavy cigarette smoker (≥2 packets per day) more than 10 years, (2) family history of cancer, (3) chronic infection of hepatitis B virus (HBV) or hepatitis C virus (HCV), and (4) elevated prostate-specific antigen (PSA) level (≥4 ng/ml). Any individual with a current diagnosis or history of any types of tumor, HIV infection, or pregnancy was excluded.
All experimental protocols were approved by the Instituto Nacional de Salud, Comité de Investigación, Lima, Peru. The methods were carried out in accordance with the relevant guidelines and regulations. Informed consent was obtained from all subjects.
4.1. Blood Draw
The subjects provided 7.5 ml of blood for CTC analysis.
4.2. CTC Isolation
The cells are selected by a new microfluidic device, the IsoPic, in the process of being commercialized, which separates the cells based on their biomechanical properties: flow rate, surface interactions, plasticity, and elasticity. The details cannot be further disclosed for intellectual property right reasons. The CTC isolation was carried out within 24 h after the blood draw with iCellate’s isolation technology according to the IsoPic operators’ manual. The IsoPic system is intended to, from a blood sample, identify, concentrate, and purify CTC to make them available as a sample to support the enumeration and analyses to support diagnosis of metastatic tumors and those nonmetastatic tumors that may release circulating tumor cells.
4.3. Cell Staining
The cells were washed in PBS for 5 minutes and then permeabilized with 0.2% Triton X-100 in PBS for 5 minutes and then washed by addition of PBS for 5 minutes.
The antibody/DAPI mix was added and incubated for 1 hour in the dark.
The cells were then washed twice with PBS for 5 minutes and mounted in a hydrophilic mounting medium with antifade and covered with a coverslip without catching air bubbles. The cells were then viewed using a microscope. The following DAPI and antibody preparations were used: DAPI (4′,6-diamino-2-phenylindole dihydrochloride, Cat. number D9542-5mg, Sigma-Aldrich), anti-Pan cytokeratin (AE1/AE3), eFluor 570 (Cat. number 41-9003-82, eBioscience), and anti-human CD45 (2D1)-FITC (Cat. number 345808, BD).
4.4. Microscopic Evaluation
The microscope system was a Nikon Eclipse Ni-E equipped with a CoolLED pE-300 light source, a CFI Plan Fluor 20x objective, and a Hamamatsu ORCA-Flash4.0 camera. The cell selection criteria were 8–25 μm cell diameter, cytoplasmic cytokeratin positivity, a DAPI-positive cell nucleus, and no CD45 reactivity. The NIS-Elements Advanced Research software package was used to assist the evaluation. The microscopic evaluation was carried out by two independent experienced operators.
Dr. Christer Ericsson owns stock in iCellate Medical and is employed as its Chief Scientific Officer.
Conflicts of Interest
Dr. Juan Castro, Dr. Luis Sanchez, Dr. Ming Lu, Tomas Castro, and Dr. Hamid R. Sharifi declare no potential conflict of interest.
Luis Sanchez contacted the patients and oversaw the blood sampling and clinical record keeping. María Teresa Nuñez oversaw the circulating tumor cell isolation and associated record keeping and the transfer of the processed samples for laboratory analyses. Ming Lu, Tomas Castro, and Hamid R. Sharifi performed the laboratory analyses, cell staining, microscopic analyses, and associated record keeping. Juan Castro and Christer Ericsson conceived of the experiments. Christer Ericsson analyzed the results and authored the manuscript. All authors reviewed the manuscript.
The authors are pleased to acknowledge the receipt of a EUREKA and European Community grant from the EUROSTARS program, grant number E!8445—CellCleanUpSystems—to Christer Ericsson.
- S. Friberg and S. Mattson, “On the growth rates of human malignant tumors: implications for medical decision making,” Journal of Surgical Oncology, vol. 65, no. 4, pp. 284–297, 1997.
- Y. Hüsemann, J. B. Geigl, F. Schubert et al., “Systemic spread is an early step in breast cancer,” Cancer Cell, vol. 13, no. 1, pp. 58–68, 2008.
- M. J. Reiter, J. E. Costello, R. B. Schwope, C. J. Lisanti, and M. B. Osswald, “Review of commonly used serum tumor markers and their relevance for image interpretation,” Journal of Computer Assisted Tomography, vol. 39, no. 6, pp. 825–834, 2015.
- C. M. Sturgeon, L. C. Lai, and M. J. Duffy, “Serum tumour markers: how to order and interpret them,” BMJ, vol. 339, article b3527, 2009.
- P. L. C. Walker and M. Crook, “Tumour marker requesting in primary care and the role of the laboratory,” Journal of Clinical Pathology, vol. 64, no. 5, pp. 443–446, 2011.
- S. J. Cohen, C. J. A. Punt, N. Iannotti et al., “Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3213–3221, 2008.
- J. S. de Bono, H. I. Scher, R. B. Montgomery et al., “Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer,” Clinical Cancer Research, vol. 14, no. 19, pp. 6302–6309, 2008.
- D. F. Hayes, M. Cristofanilli, G. Thomas Budd et al., “Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival,” Clinical Cancer Research, vol. 12, no. 14, pp. 4218–4224, 2006.
- W. J. Allard, J. Matera, M. C. Miller et al., “Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases,” Clinical Cancer Research, vol. 10, no. 20, pp. 6897–6904, 2004.
- A. Paxton, “Unraveling metastasis with circulating tumor cells,” CAP Today, 2014.
- J. F. Swennenhuis, G. van Dalum, L. L. Zeune, and L. W. M. M. Terstappen, “Improving the CellSearch® system,” Expert Review of Molecular Diagnostics, vol. 16, no. 12, pp. 1291–1305, 2016.
- J. Castro, C. Ericsson, P. Cashin, and H. Mahteme, “Preliminary finding: detection of circulating cancer cells in blood from a patient with peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy,” Surgery: Current Research, vol. 2, no. 3, 2012.
- M. Cristofanilli, G. T. Budd, M. J. Ellis et al., “Circulating tumor cells, disease progression, and survival in metastatic breast cancer,” New England Journal of Medicine, vol. 351, no. 8, pp. 781–791, 2004.
- R. A. Smith, K. Andrews, D. Brooks et al., “Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening,” CA: A Cancer Journal for Clinicians, vol. 66, no. 2, pp. 95–114, 2016.
- E. Racila, D. Euhus, A. J. Weiss et al., “Detection and characterization of carcinoma cells in the blood,” Proceedings of the National Academy of Sciences, vol. 95, no. 8, pp. 4589–4594, 1998.
- J. M. G. Wilson and G. Jungner, “Principles and practice of screening for disease,” in Public Health Papers No. 34, World Health Organization, Geneva, 1968.
- K. Podsypanina, Y. C. N. Du, M. Jechlinger, L. J. Beverly, D. Hambardzumyan, and H. Varmus, “Seeding and propagation of untransformed mouse mammary cells in the lung,” Science, vol. 321, no. 5897, pp. 1841–1844, 2008.
- D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
- D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000.
Copyright © 2018 Juan Castro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.